Upfront Briefing
Bristol Myers Squibb opened the week by writing a $600M upfront check to Hengrui for a 13-program collaboration worth up to ~$15.2B in biobucks — another reminder that China sourcing is no longer a side quest. Elsewhere, Roche picked up a CE mark for its Alzheimer's blood test in Europe, and Novo kept the obesity drumbeat going with higher-dose Wegovy data showing nearly 28% weight loss in early responders.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,412.8 |
+0.2% |
+6.8% |
| Nasdaq 100 |
29,320.7 |
+0.3% |
+16.7% |
| Russell 2000 |
2,870.6 |
+0.3% |
+7.1% |
| Healthcare (XLV) |
143.0 |
(0.3%) |
(7.5%) |
| Biotech (XBI) |
134.8 |
0.0% |
+7.5% |
| Nasdaq Biotech (NBI) |
5,930.8 |
+0.1% |
+0.6% |
| Clinical Trials (BBC) |
44.7 |
+0.2% |
+9.0% |
|
- Indices ground to fresh closing records (S&P 500 above 7,400 for the first time, Russell 2000 also at a record) as chip and AI-linked names extended Friday's payrolls-led rally, even as oil firmed on Trump's rejection of Iran's latest proposal.
- Defensive healthcare lagged the green tape — XLV (0.3%) and a flat XBI 0.0% — with flows staying rotational rather than defensive; Moderna (+~8%) was the standout single-name biotech mover on disclosed hantavirus research plus NEJM-published flu Ph3 data.
- Market data: U.S. close Mon 11-May-2026.
The Big 3
|
1
|
Bristol Myers Squibb, Hengrui strike broad collaboration
|
- BMS and Hengrui announced a 13-program global strategic collaboration in oncology, hematology and immunology: $600M upfront + $175M first anniversary + $175M contingent second anniversary ($950M near-term) and up to ~$15.2B total in milestones plus tiered royalties. BMS gets ex-China rights to 4 Hengrui onco/heme assets; Hengrui gets China rights to 4 BMS immunology assets; 5 additional programs to be jointly discovered using Hengrui's discovery platform. HSR-conditioned; close expected Q3'26.
- Why it matters: The $600M upfront is among the largest ever written for a China-out portfolio deal, and signals BMS is paying for breadth ahead of Eliquis/Opdivo erosion rather than holding out for single-asset clarity. Joint-discovery optionality positions this more as a platform partnership than a license. Read-through: it tightens valuation comps for pre-clinical/early-clinical China onco/I&I peers still seeking ex-China partners, and adds to the AstraZeneca-CSPC / GSK-Hengrui template that has effectively re-priced the China asset pool over the last 12 months.
- Source: Fierce Biotech
- More: PR
|
|
2
|
Roche wins CE mark for Alzheimer's blood test pTau217
|
- Roche received a CE mark for Elecsys pTau217, the first Roche blood test to detect Alzheimer's pathology in symptomatic patients. The assay runs on the cobas pro platform already installed across European labs.
- Why it matters: pTau217 is now consensus as the most accurate plasma biomarker for amyloid pathology (>90% concordance with PET/CSF in symptomatic patients), and CE marking moves AD workups out of specialist centres into community-accessible pathways. The direct read-through for investors is a wider funnel into amyloid therapies — LEQEMBI (Eisai/Biogen) and Kisunla (Lilly) — via earlier and broader patient identification. It also extends Roche's diagnostics moat against C2N (PrecivityAD2), Quanterix and Fujirebio competing for the same pre-screening lane.
- Source: PR
|
| 3 | Novo presents higher-dose Wegovy obesity data |
- Novo presented new analyses from STEP UP at the European Congress on Obesity showing higher-dose Wegovy (7.2 mg) drove ~28% mean weight loss in early responders (subgroup with strong initial response by week 20), vs ~21% for the overall 7.2 mg arm and ~14–15% for 2.4 mg in original STEP.
- Why it matters: 28% is a post-hoc responder subset, not a label number — but it positions semaglutide credibly versus tirzepatide (~22–25% in SURMOUNT) and retatrutide (~24% in Ph2) at peer-equivalent depth. With Lilly's orforglipron (oral) and retatrutide moving fast, Novo's defence is increasingly dose escalation plus early identification of high responders. For investors, the data supports peak-sales upside on the 7.2 mg label expansion already filed in select markets, and reinforces that obesity competition is shifting from "which class" to depth, formulation and sub-population.
- Source: PR
|
Everything Else that broke
- Daiichi Sankyo confirmed FY25 results and unveiled the Sixth Mid-term Plan (FY26–FY30) as previewed Monday: revenue JPY 2,123B (+12.6%); 2030 targets JPY 3T revenue / JPY 600B operating profit / JPY 2.3T from oncology; aiming top-5 global oncology by 2035. Announced ~$1.3B cost optimization, a JPY 200B share buyback, and cancellation of 31.5M treasury shares (10 June). — Fierce Pharma
- Moderna (+~8% Monday) on disclosed preclinical hantavirus research with USAMRIID and Korea University (cruise-ship Andes outbreak), layered on top of last week's NEJM-published mRNA-1010 flu Ph3 data. Inovio, Novavax spiked early then faded by close. — CNBC
- Optum Rx unveiled a transparent fee-based pharmacy care model — full implementation by Jan 2028, replacing manufacturer-price- and volume-linked structures with flat service fees across its ~61M-member PBM book. — Endpoints
- BrightGene posts Phase III BGM0504 (GLP-1/GIP) topline: 19.3% mean weight loss, 16.5 cm waist reduction, with hypertensive-population SBP/DBP improvements and triglyceride / uric acid reductions; NDA submission planned in China. — PR
- Makary watch: did not appear at Monday's Oval Office event with other top public-health officials; still scheduled to testify before Senate Appropriations Wednesday — the next visible catalyst on the FDA leadership story. — CBS News
- Tonix (TNXP) reports first post-approval quarter with early TONMYA launch metrics. — PR
- Catalyst posts Q1 revenue growth ahead of pending Angelini close. — PR
- Erasca reports early efficacy / safety update for ERAS-0015 alongside Q1. — PR
- Coherus Oncology reports Q1, LOQTORZI revenue. — PR
- Pliant doses first participant in FORTIFY expansion. — PR
- Aura says Ph3 CoMpass nears enrollment completion. — PR
- Elicio extends runway beyond expected DFS readout. — PR
- Biomea Fusion reports Q1 financials and business update. — PR
- BioCentury highlights efforts to enable AAV redosing. — BioCentury
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Bristol Myers Squibb / Hengrui — 13-program global strategic collaboration in oncology, hematology and immunology; $600M upfront + $175M anniversary payments in 2027 and 2028, up to ~$15.2B in milestones, tiered royalties; expected close Q3'26. — Fierce Biotech
- Delos Capital and AP Biosciences launch antibody-focused NewCo platform. — PR
VC / Private Financings
- No notable VC / private financings since the last edition.
IPOs / Follow-Ons
- No notable IPOs / follow-ons since the last edition.
|
